Definition and treatment of locally advanced basal cell carcinoma. Expert consensus
DOI:
https://doi.org/10.29176/2590843X.1665Keywords:
Basal cell carcinoma, Consensus, Drug therapy, Skin neoplasms, TherapeuticsAbstract
Objective: To generate recommendations for the management of locally advanced basal cell carcinoma (LABCC) in the Colombian context, based on consensus of experts.
Materials and methods: A formal consensus was made, with nominal group methodology. A systematic literature search was conducted to support the development of consensus. A group of experts in the management of locally advanced basal cell carcinoma in Colombia was invited to participate and a conduction group and an assessment group were established (panel of fourteen experts). The scope and questions of the consensus were previously defined. The groups worked in virtual meetings and finally in two face-to-face sessions the recommendations were defined.
Results: The LABCC is defined as a tumor larger than 2 cm, with involvement of deep structures and one or more of the following criteria: recurrent tumor, poorly defined borders, histologically aggressive, with perineural invasion. To define the proper management, the panel recommended taking into account tumor criteria, therapy criteria, and patient criteria. The panel recommended that in patients with LABCC, in whom surgery is not adequate, the treatment of choice is vismodegib.
Conclusions: The results of this work reflect the definition of LABCC for the Colombian context, and the general recommendations for its management, including specific aspects of medical therapy with vismodegib.
Author Biographies
Elkin Peñaranda, Médico, Dermatólogo Oncólogo. Hospital Universitario la Samaritana. Clínica los Nogales. Bogotá
Médico, Dermatólogo Oncólogo. Hospital Universitario la Samaritana. Clínica los Nogales. Bogotá
Xavier Rueda-Cadena, Médico, Dermatólogo Oncólogo. Instituto Nacional de Cancerología. Bogotá.
Médico, Dermatólogo Oncólogo. Instituto Nacional de Cancerología. Bogotá.
Santiago Andrés Ariza-Gómez, Dermatólogo Oncólogo, Hospital de San José. Bogotá.
Dermatólogo Oncólogo, Hospital de San José. Bogotá.
Iván Medina, Médico. Oncólogo. Clínica Bonnadona. Barranquilla.
Médico. Oncólogo. Clínica Bonnadona. Barranquilla.
Guillermo Sánchez-Vanegas, Médico, MSc. Epidemiología Clínica. PhD. Salud Pública. Fundación Universitaria de Ciencias de la Salud. Epidemiología Clínica. SIIES: Investigación y Educación en Salud. Bogotá-Colombia.
Médico, MSc. Epidemiología Clínica. PhD. Salud Pública. Fundación Universitaria de Ciencias de la Salud. Epidemiología Clínica. SIIES: Investigación y Educación en Salud. Bogotá-Colombia.
References
Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069-80. https://doi.org/10.1111/j.1365-2133.2012.10830.x
Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol. 2010;146(3):283-7. https://doi.org/10.1001/archdermatol.2010.19
Sánchez G, Nova J, de la Hoz F, Castañeda C. Incidencia de cáncer de piel en Colombia. Años 2003-2007. Piel. 2011;26(4):171-7. https://doi.org/10.1016/j.piel.2010.10.028
Nova-Villanueva J, Sánchez-Vanegas G, Porras De Quintana L. [Skin cancer: A Colombian reference centre's epidemiological profile 2003-2005]. Rev Salud Publica (Bogota). 2007;9(4):595-601. https://doi.org/10.1590/s0124-00642007000400012
Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ. 2003;327(7418):794-8. https://doi.org/10.1136/bmj.327.7418.794
Peris K, Tambone S, Kostaki D, Varrassi E, Fargnoli MC. Treatments of advanced basal cell carcinoma: a review of the literature. G Ital Dermatol Venereol. 2016;151(1):77-86.
Goldenberg G, Karagiannis T, Palmer JB, Lotya J, O'Neill C, Kisa R, et al. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: A retrospective cohort study. J Am Acad Dermatol. 2016;75(5):957-66. e2. https://doi.org/10.1016/j.jaad.2016.06.020
Gaulin C, Sebaratnam DF, Fernández-Peñas P. Quality of life in non-melanoma skin cancer. Australas J Dermatol. 2015;56(1):70-6. https://doi.org/10.1111/ajd.12205
Acosta A, Nova J, Sánchez, Rueda X, Rodríguez A, Valbuena M. Guía de atención integral con evaluación económica para la prevención, el diagnóstico, el tratamiento y el seguimiento del cáncer de piel no melanoma: carcinoma basocelular. Rev Asoc Colomb Dermatol. 2015;23(4):258-96. https://doi.org/10.29176/2590843X.282
Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019;118:10-34. https://doi.org/10.1016/j.ejca.2019.06.003
Peris K, Licitra L, Ascierto PA, Corvo R, Simonacci M, Picciotto F, et al. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Future Oncol. 2015;11(4):703-12. https://doi.org/10.2217/fon.14.281
Dummer R, Ascierto PA, Basset-Seguin N, Dréno B, Garbe C, Gutzmer R, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020;34(9):1944-56. https://doi.org/10.1111/jdv.16230
Dubey AK, Dubey S, Handu SS, Qazi MA. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma. J Postgrad Med. 2013;59(1):48-50. https://doi.org/10.4103/0022-3859.109494
Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 2013;19(9):2289-93. https://doi.org/10.1158/1078-0432.CCR-12-1956
Xie P, Lefrançois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and metaanalysis. J Am Acad Dermatol. 2018;79(6):1089-100.e17. https://doi.org/10.1016/j.jaad.2018.07.004
Maly TJ, Sligh JE. Defining locally advanced Basal cell carcinoma. J Drugs Dermatol. 2014;13(5):528-9.
Migden MR, Chang ALS, Dirix L, Stratigos AJ, Lear JT. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treat Rev. 2018;64:1-10. https://doi.org/10.1016/j.ctrv.2017.12.009
Amici JM, Battistella M, Beylot-Barry M, Chatellier A, Dalac-Ra S, Dreno B, et al. Defining and recognising locally advanced basal cell carcinoma. Eur J Dermatol. 2015;25(6):586-94. https://doi.org/10.1684/ejd.2015.2641
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55.
Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2(3):187-93. https://doi.org/10.1200/JCO.1984.2.3.187
Basset-Seguin N, Hauschild A, Kunstfeld R, Grob J, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334-48. https://doi.org/10.1016/j.ejca.2017.08.022
Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332. https://doi.org/10.1186/s12885-017-3286-5
Hehlgans S, Booms P, Güllülü Ö, Sader R, Rödel C, Balermpas P, et al. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib. Int J Mol Sci. 2018;19(9):2485. https://doi.org/10.3390/ijms19092485
Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, et al. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma. Oncotarget. 2016;7(46):76118-24. https://doi.org/10.18632/oncotarget.12660
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171-9. https://doi.org/10.1056/NEJMoa1113713
Juhasz ML, Marmur ES. Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology. J Drugs Dermatol. 2014;13(6):729-33.
Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, et al. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. Oncologist. 2016;21(10):1218-29. https://doi.org/10.1634/theoncologist.2016-0186
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
